Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Nuformix Plc ( (GB:NFX) ) has issued an update.
Nuformix plc has announced a placing to raise £168,750 by issuing 250 million new ordinary shares, equivalent to 17.6% of its current issued share capital. The funds will primarily support ongoing partnering discussions for its NXP002 program, an inhaled treatment for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, as well as general corporate purposes. The shares are expected to begin trading on the London Stock Exchange on 5 February 2025.
More about Nuformix Plc
Nuformix is a pharmaceutical development company focusing on unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering, developing, and patenting novel drug forms with enhanced physical properties, aiming to create differentiated products for new indications, thereby opening new commercial opportunities.
YTD Price Performance: 70.0%
Average Trading Volume: 64,513,966
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £2.06M
For a thorough assessment of NFX stock, go to TipRanks’ Stock Analysis page.
